Table 4.

Univariate outcome analysis of recurrence-free survival and overall survival after pulmonary metastasectomy.

	Recurrence-free survival		Overall survival
	Mean survival (months)	p-value	Mean survival (months)	p-value
Sex
Male	17 (9–25)	0.081	67 (49–84)	0.685
Female	31 (17–33)		66 (44–87)
Age (years)
<64 y	22 (13–32)	0.857	51 (39–62)	0.714
≥ 64 y	26 (15–38)		69 (49–89)
Location
Colon	19 (13–25)	0.796	68 (48–88)	0.743
Rectum	28 (16–40)		53 (41–65)
UICC stage
I + II	23 (12–35)	0.721	43 (32–55)	0.061
III + IV	26 (17–36)		87 (66–107)
Chemotherapy before metastasectomy
Yes	24 (16–33	0.683	70 (53–87)	0.538
No	26 (10–41)		45 (30–59)
Chemotherapy after metastasectomy
Yes	22 (15–29)	0.589	59 (46–71)	0.269
No	29 (10–48)		97 (70–125)
Previous liver metastasis
Yes	14 (7–21)	0.055	49 (34–63)	0.447
No	30 (20–40)		70 (52–88)
Lung metastasis free survival
<36	23 (15–31)	0.952	69 (50–89)	0.931
≥36	22 (12–32)		55 (41–69)
Number of metastasis
Singular	20 (14–25)	0.448	72 (54–89)	0.551
Multiple	33 (14–53)		56 (28–84)
PD1 – Tumor-infiltrating lymphocytes
Low	24 (16–33)	0.766	78 (60–96)	0.011
High	24 (12–35)		35 (25–44)
PD1 – Tumor cells
Low	28 (14–41)	0.918	83 (57–109)	0.425
High	21 (15–28)		59 (45–74)
PD-L1 – Tumor-infiltrating lymphocytes
Negative	15 (6–23)	0.310	38 (29–46)	0.307
Positive	26 (17–35)		73 (55–90)
PD-L1 – Tumor cells
Negative	16 (10–23)	0.538	74 (51–98)	0.628
Positive	26 (17–35)		71 (52–89)